Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:FRMM NASDAQ:SGMT NASDAQ:WHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.81+2.0%$2.29$1.09▼$3.40$200.96M0.61802,844 shs449,391 shsFRMMForum Markets$4.97+2.1%$4.03$1.76▼$174.60$72.28M1.45966,876 shs265,990 shsSGMTSagimet Biosciences$7.06+2.9%$6.49$4.00▼$11.41$230.02M3.411.13 million shs397,359 shsWHWKWhitehawk Therapeutics$4.40+1.4%$4.04$1.57▼$5.49$217.58M0.77231,999 shs196,170 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-8.97%-19.68%-24.79%-10.35%+19.93%FRMMForum Markets+2.10%+15.95%-16.75%+486,999,900.00%+486,999,900.00%SGMTSagimet Biosciences+1.03%-4.99%-9.86%+25.87%+88.98%WHWKWhitehawk Therapeutics+3.83%-9.21%+8.77%+21.57%+433,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.81+2.0%$2.29$1.09▼$3.40$200.96M0.61802,844 shs449,391 shsFRMMForum Markets$4.97+2.1%$4.03$1.76▼$174.60$72.28M1.45966,876 shs265,990 shsSGMTSagimet Biosciences$7.06+2.9%$6.49$4.00▼$11.41$230.02M3.411.13 million shs397,359 shsWHWKWhitehawk Therapeutics$4.40+1.4%$4.04$1.57▼$5.49$217.58M0.77231,999 shs196,170 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-8.97%-19.68%-24.79%-10.35%+19.93%FRMMForum Markets+2.10%+15.95%-16.75%+486,999,900.00%+486,999,900.00%SGMTSagimet Biosciences+1.03%-4.99%-9.86%+25.87%+88.98%WHWKWhitehawk Therapeutics+3.83%-9.21%+8.77%+21.57%+433,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$3.63100.28% UpsideFRMMForum Markets 2.50Moderate Buy$10.00101.17% UpsideSGMTSagimet Biosciences 2.67Moderate Buy$25.75264.73% UpsideWHWKWhitehawk Therapeutics 2.50Moderate Buy$7.3366.67% UpsideCurrent Analyst Ratings BreakdownLatest FRMM, ALEC, SGMT, and WHWK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026FRMMForum Markets Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/19/2026SGMTSagimet Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$35.00 ➝ $12.005/15/2026FRMMForum Markets BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$5.00 ➝ $9.005/11/2026FRMMForum Markets Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.005/11/2026FRMMForum Markets Clear StrSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/8/2026WHWKWhitehawk Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.005/4/2026ALECAlector Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026ALECAlector Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$2.005/4/2026SGMTSagimet Biosciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $49.005/1/2026SGMTSagimet Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/29/2026SGMTSagimet Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $25.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$21.05M9.55N/AN/A$0.28 per share6.46FRMMForum Markets$6.55M11.03N/AN/A$12.59 per share0.39SGMTSagimet Biosciences$2M115.01N/AN/A$3.42 per share2.06WHWKWhitehawk Therapeutics$7.14M30.47N/AN/A$2.89 per share1.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)FRMMForum Markets-$450.52M-$36.07N/A31.07N/AN/A-242.09%-135.46%N/ASGMTSagimet Biosciences-$51.04M-$1.34N/AN/AN/AN/A-37.57%-35.52%8/12/2026 (Estimated)WHWKWhitehawk Therapeutics-$20.60M-$1.68N/AN/AN/AN/A-79.63%-74.01%N/ALatest FRMM, ALEC, SGMT, and WHWK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FRMMForum MarketsN/A-$3.64N/A-$3.58N/A$2.86 million5/12/2026Q1 2026SGMTSagimet Biosciences-$0.39-$0.33+$0.06-$0.33N/AN/A5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million5/7/2026Q1 2026WHWKWhitehawk Therapeutics-$0.36-$0.32+$0.04-$0.32N/AN/A3/31/2026Q4 2025FRMMForum MarketsN/A-$12.14N/A-$12.24N/A$2.44 million3/12/2026Q4 2025WHWKWhitehawk Therapeutics-$0.55-$0.34+$0.21-$0.34N/AN/A3/11/2026Q4 2025SGMTSagimet Biosciences-$0.43-$0.29+$0.14-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AFRMMForum MarketsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.805.255.25FRMMForum Markets0.156.196.19SGMTSagimet BiosciencesN/A20.3320.34WHWKWhitehawk TherapeuticsN/A11.3611.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%FRMMForum Markets4.07%SGMTSagimet Biosciences87.86%WHWKWhitehawk Therapeutics52.08%Insider OwnershipCompanyInsider OwnershipALECAlector8.30%FRMMForum Markets15.10%SGMTSagimet Biosciences14.70%WHWKWhitehawk Therapeutics49.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270111.03 million101.81 millionOptionableFRMMForum Markets714.54 million12.35 millionN/ASGMTSagimet Biosciences832.58 million27.80 millionOptionableWHWKWhitehawk Therapeutics2149.45 million24.78 millionN/AFRMM, ALEC, SGMT, and WHWK HeadlinesRecent News About These CompaniesWhitehawk Therapeutics (NASDAQ:WHWK) Stock Price Down 4.9% - Here's What HappenedJune 2 at 1:40 AM | americanbankingnews.comWhitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026May 30, 2026 | gurufocus.comWhitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026May 30, 2026 | prnewswire.comWhitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare ConferenceMay 28, 2026 | prnewswire.comWHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital RaiseMay 21, 2026 | finance.yahoo.comWhitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-PayloadMay 21, 2026 | prnewswire.comWhitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation SummitMay 20, 2026 | prnewswire.comWhitehawk Therapeutics officer Ball sells $201k in stockMay 18, 2026 | investing.comWhitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology ForumMay 15, 2026 | prnewswire.comWhitehawk’s First-in-Human PTK7 ADC Trial Moves Ahead: What Investors Should KnowMay 14, 2026 | theglobeandmail.comWhitehawk Therapeutics secures $87.5M PIPE financingMay 14, 2026 | seekingalpha.comWhitehawk Therapeutics Announces $87.5M Private Placement Equity FinancingMay 13, 2026 | prnewswire.comWhitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Rating of "Moderate Buy" from BrokeragesMay 11, 2026 | marketbeat.comWhitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026 | finanznachrichten.deWhitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026 | prnewswire.comWhitehawk Therapeutics (WHWK) price target increased by 10.29% to 6.38April 28, 2026 | msn.comWhitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026April 19, 2026 | prnewswire.comInsider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) CFO Sells 77,000 Shares of StockApril 18, 2026 | insidertrades.comWhitehawk Therapeutics, Inc. Common Stock (WHWK) Institutional HoldingsApril 17, 2026 | nasdaq.comCitizens Initiates Coverage of Whitehawk Therapeutics (WHWK) with Market Outperform RecommendationApril 17, 2026 | msn.comWhitehawk jumps as Citizens issues Outperform rating ahead of trial dataApril 17, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFRMM, ALEC, SGMT, and WHWK Company DescriptionsAlector NASDAQ:ALEC$1.81 +0.04 (+1.97%) Closing price 04:00 PM EasternExtended Trading$1.80 -0.01 (-0.28%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Forum Markets NASDAQ:FRMM$4.97 +0.10 (+2.07%) Closing price 03:59 PM EasternExtended Trading$4.82 -0.15 (-3.06%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forum Markets Inc is a digital asset platform modernizing capital markets through the tokenization of institutional-grade real-world assets on Ethereum. The company structures cash-generating assets on blockchain-based infrastructure to facilitate liquidity, investor access, and primary and secondary market activity. It combines traditional asset management practices with digital market infrastructure to support the origination, distribution, and trading of real-world assets.Sagimet Biosciences NASDAQ:SGMT$7.06 +0.20 (+2.92%) Closing price 04:00 PM EasternExtended Trading$7.06 +0.01 (+0.07%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Whitehawk Therapeutics NASDAQ:WHWK$4.40 +0.06 (+1.38%) Closing price 04:00 PM EasternExtended Trading$4.43 +0.03 (+0.68%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
